País: Australia
Idioma: inglés
Fuente: Department of Health (Therapeutic Goods Administration)
atazanavir sulfate, Quantity: 341.71 mg (Equivalent: atazanavir, Qty 300 mg)
Cipla Australia Pty Ltd
Atazanavir sulfate
Capsule, hard
Excipient Ingredients: lactose monohydrate; crospovidone; magnesium stearate; purified water; titanium dioxide; iron oxide red; Gelatin; sodium lauryl sulfate
Oral
30 capsules, 60 capsules
(S4) Prescription Only Medicine
Atazanavir is indicated for the treatment of HIV 1 infection, in combination with other antiretroviral agents. This indication is based on analyses of plasma HIV-1 RNA levels and CD4 cell counts from controlled studies (See Clinical Trials).
Visual Identification: White to pale yellow granules filled in size 00 hard gelatin capsule with maroon cap & white body spin printed with 'Cipla 300' on cap with white ink.; Container Type: Bottle; Container Material: HDPE; Container Life Time: 15 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Child resistant closure
Licence status A
2017-08-30